Sunitinib Malate

CAS No. 341031-54-7

Sunitinib Malate( SU11248 )

Catalog No. M14156 CAS No. 341031-54-7

Potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 33 In Stock
100MG 45 In Stock
200MG 58 In Stock
500MG 71 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Sunitinib Malate
  • Note
    Research use only, not for human use.
  • Brief Description
    Potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor.
  • Description
    Potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor. Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.
  • In Vitro
    Sunitinib Malate is also a good inhibitor of KIT and FLT-3. In RS4;11 cells (FLT3-WT), treatment with Sunitinib (SU11248) inhibits FLT3-WT phosphorylation in a dose-dependent manner with IC50 of approximately 250 nM. In MV4;11 cells that express FLT3-ITD, Sunitinib inhibits FLT3-ITD phosphorylation in a dose-dependent manner with an IC50 of 50 nM following a 2-hour treatment.In biochemical assays, Sunitinib (SU11248) exhibits competitive inhibition (with regard to ATP) against Flk-1 and PDGFRβ with Ki values of 9 nM and 8 nM, respectively. Sunitinib is also a competitive, albeit less potent, inhibitor of FGFR1 tyrosine kinase activity, with a Ki value of 0.83 μM. In addition to these three structurally related split kinase domain RTKs, the activity of Sunitinib has also been evaluated against a broad panel of additional tyrosine and serine/threonine kinases. In these biochemical assays, the IC50 values for Sunitinib are generally at least 10-fold higher than those for Flk-1 and PDGFR (e.g., IC50 values of: >10 μM for EGFR and Cdk2; 4 μM for Met; 2.4 μM for IGFR-1; 0.8 μM for Abl; and 0.6 μM for Src).
  • In Vivo
    Sunitinib Malate has very good oral bioavailability, is highly efficacious in a number of preclinical tumor models, and is well tolerated at efficacious doses. Sunitinib (80 mg/kg/day) inhibits the growth of established SF763T and Colo205 tumor xenografts in athymic mice. Sunitinib (SU11248) treatment effectively inhibits the growth of established tumor xenografts.
  • Synonyms
    SU11248
  • Pathway
    Angiogenesis
  • Target
    FGFR
  • Recptor
    FGFR1| PDGFRβ| VEGFR2
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    341031-54-7
  • Formula Weight
    532.56
  • Molecular Formula
    C26H33FN4O7
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 15 mg/mL (28.16 mM)
  • SMILES
    CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C.C([C@@H](C(=O)O)O)C(=O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sun L, et al. J Med Chem, 2003, 46(7), 1116-1119.
molnova catalog
related products
  • Sunitinib Malate

    Potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor.

  • Derazantinib

    Derazantinib (ARQ-087) is a novel potent, ATP competitive multi-kinase inhibitor with IC50 of FGFR1/2/3 with IC50 of 1.8-4.5 nM.

  • Sucralfate

    Sucralfate is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.